MetaCap

ADARx Pharmaceuticals (ADRX) vs Damora Therapeutics (DMRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Damora Therapeutics is the larger company by market cap ($1.44 billion vs $1.42 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADRX-33.90%DMRA+12.39%
+20%-8%-36%
Sep 25, 20261 yearNov 20, 2026
ADRX-33.90%DMRA+12.39%
+17%-10%-36%
Sep 21, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADRX versus DMRA key metrics
MetricADRXDMRA
Share price$12.79$23.22
Market cap$1.42B$1.44B
1-day change-9.68%-4.44%
YTD return—+0.91%
1-year return—+38.46%
5-year return—-68.83%
P/E ratio (TTM)—13.58
EPS (TTM)$-6.75$1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-209.84M
52-week high$23.21$38.33
52-week low$12.50$15.76
Distance from 52-week high-44.89%-39.41%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+167.79%+101.46%
Average volume650.63K584.28K
Shares outstanding111.19M61.90M
Employees1007
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ADARx Pharmaceuticals

ADRX stock →

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Damora Therapeutics

DMRA stock →

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

ADRX vs DMRA FAQ

Which is bigger, ADARx Pharmaceuticals or Damora Therapeutics?

Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.44B compared with $1.42B for ADARx Pharmaceuticals (ADRX).

Are ADARx Pharmaceuticals and Damora Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons